Pfizer: colorectal cancer mortality halved

Published: 2025-05-30 10:41:29 ET PFE

Published on 05/30/2025 at 10:41

Pfizer announced Friday that a treatment based on its oral small molecule Braftovi has halved the risk of death in aggressive metastatic colorectal cancer in a Phase 3 clinical trial.The combination of its experimental tablet with cetuximab (Erbitux) or mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) reduced the risk of death by 51% in patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation, according to the trial results.The study also showed a 47% reduction in the risk of disease progression or death compared to standard treatment, thereby meeting the trial's two primary endpoints.In a press release, Pfizer emphasized that this treatment is the first and only targeted therapy to demonstrate a survival benefit in newly diagnosed patients with the BRAF V600E mutation, which is often associated with a poor prognosis and poor response to conventional chemotherapy.Metastatic colorectal cancer is the third most common cancer worldwide, and BRAF gene mutations, including the V600E variant, are found in approximately 8% to 12% of patients.The data was presented at the ASCO Annual Meeting, currently being held in Chicago.Copyright (c) 2025 CercleFinance.com. All rights reserved.